Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:34:16.989Z.
Calculation as of: 2026-10-06T17:34:16.989Z.
Quote observation: 2026-10-06T17:29:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
PE RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$940.80M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.18M
PE Ratio
70.28
TTM Avg
118.14
3Y Avg
119.36
5Y Avg
99.91
Market Cap
$974.72M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $940.80M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $942.80M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $947.79M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.78M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $927.79M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $965.56M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.98M | 43.78 | 37.03 | 45.62 | 62.08 |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.18M | 70.28 | 118.14 | 119.36 | 99.91 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $974.72M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $977.74M | 14.87 | 18.35 | 18.35 | 18.35 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$17.57
Forward EPS (Est.)
$-4.43
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
